drugset / Trial / NCT02355756
Biomarker Development for Future PAC1 Antagonists With Maxadilan
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This will be a single center, open-label study in healthy male subjects between 18 and 45 years old to determine the dose response profiles of dermal blood flow in response to intradermal injections of maxadilan. The study will consist of 2 parts: Part I: dose and time finding and Part II: reproducibility over time.
Timeline
- Start
- 2015-01
- Primary completion
- 2015-04
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maxadilan | Unknown | — | Other |
Indications
No indication recorded.